After the subsequent 6-month follow-up period, 34 patients were ultimately considered as having a recurrent or progressive glioma (3 IDH-mutant astrocytomas, 6 IDH-wildtype astrocytomas, 6 IDH-mutant and 1p/19q co-deleted oligodendrogliomas, 17 IDH-wildtype GBM and 2 IDH-mutant GBM) with 4 cases exhibiting a second recurrence and 2 cases a third recurrence. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).